Press release
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech
Osteosarcoma Market
DelveInsight's "Osteosarcoma - Market Insight, Epidemiology, And Market Forecast - 2032 [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] report offers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Some of the key facts of the Osteosarcoma Market Report:
- The total Osteosarcoma market size is estimated to grow with a significant CAGR during the study period (2019-2032).
- As per DelveInsight estimates, the total incident population of osteosarcoma in the 7MM was approximately 2,300 in 2023.
- The United States recorded the highest number of osteosarcoma cases, with around 1,200 cases in 2023.
- The highest number of osteosarcoma incident cases in the US in 2023 was observed in the 0-24 years age group, with approximately 500 cases.
- In January 2025, GSK announced that its investigational antibody-drug conjugate, GSK'227, received Breakthrough Therapy designation from the FDA for the treatment of relapsed or refractory osteosarcoma in patients who had progressed after at least two prior lines of therapy.
- In October 2024, OS Therapies enrolled the last patient in the Phase II trial of OST-HER2 for the treatment of osteosarcoma.
- In September 2024, Zentalis Pharmaceuticals announced that the Food and Drug Administration (FDA) had lifted partial clinical hold upon azenosertib studies which included study of osteosarcoma
- Leading Osteosarcoma therapies include ALMB-0168, Naxitamab, OST-HER2, Vactosertib, Surufatinib, and others.
- Leading companies in the Osteosarcoma market include Takeda, Acrotech Biopharma, Bayer, Exelixis, Nektar Therapeutics, Eisai, Y-mAbs Therapeutics, GlaxoSmithKline/Novartis, Aadi Bioscience, Vaccinex, Inc., National Cancer Institute/Assaf-Harofeh Medical Center, Eleison Pharmaceuticals, Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech, AlaMab Therapeutics, CSPC Pharmaceutical, OS Therapies, MedPacto, Hutchmed, and others.
To know in detail about the Osteosarcoma market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Osteosarcoma Market Forecast [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Osteosarcoma Overview
Osteosarcoma, also known as osteogenic sarcoma, is the most common type of bone cancer, primarily originating in osteoblast cells. It typically affects long bones, especially around the knee, but can also develop in the thighbone, lower leg, upper arm, pelvis, shoulder, skull, or other bones. The cancer may invade nearby tissues like tendons and muscles and has the potential to spread through the bloodstream to other organs or bones.
Get a Free sample for the Osteosarcoma Market Report: https://www.delveinsight.com/report-store/osteosarcoma-market [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Osteosarcoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Osteosarcoma Epidemiology Segmentation:
The Osteosarcoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
- Age-Specific Incident Cases of Osteosarcoma in the US
- Gender-Specific Incident Cases of Osteosarcoma in the US
- Total Incident Cases of Osteosarcoma in the US
- Stage-Specific Incident Cases of Osteosarcoma in the US
- Sub-types specific Incident Cases of Osteosarcoma in the US
- Site-specific Incident Cases of Osteosarcoma in the US
Download the report to understand which factors are driving Osteosarcoma epidemiology trends @ Osteosarcoma Epidemiology Forecast [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Osteosarcoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteosarcoma market or expected to be launched during the study period. The analysis covers the Osteosarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Osteosarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Osteosarcoma Market Strengths
- Ongoing research in targeted therapies, immunotherapy, and combination treatments is improving survival rates and expanding treatment options for osteosarcoma patients.
- Growing awareness campaigns and improved diagnostic techniques are enabling earlier detection, leading to better treatment outcomes and market growth.
Osteosarcoma Market Weaknesses
- Despite advancements, treatment for metastatic or recurrent osteosarcoma remains challenging, with limited effective therapies available.
- The high cost of osteosarcoma treatments, including chemotherapy and emerging targeted therapies, may limit patient access, especially in low-income regions.
Scope of the Osteosarcoma Market Report
- Study Period: 2019-2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Osteosarcoma Companies: Takeda, Acrotech Biopharma, Bayer, Exelixis, Nektar Therapeutics, Eisai, Y-mAbs Therapeutics, GlaxoSmithKline/Novartis, Aadi Bioscience, Vaccinex, Inc., National Cancer Institute/Assaf-Harofeh Medical Center, Eleison Pharmaceuticals, Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech, AlaMab Therapeutics, CSPC Pharmaceutical, OS Therapies, MedPacto, Hutchmed, and others.
- Key Osteosarcoma drugs: ALMB-0168, Naxitamab, OST-HER2, Vactosertib, Surufatinib, and others.
- Osteosarcoma Therapeutic Assessment: Osteosarcoma currently marketed, and Osteosarcoma emerging therapies
- Osteosarcoma Market Dynamics: Osteosarcoma market drivers and Osteosarcoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Osteosarcoma Unmet Needs, KOL's views, Analyst's views, Osteosarcoma Market Access and Reimbursement
To learn more about the key players and advancements in the Osteosarcoma Treatment Landscape, visit the Osteosarcoma Market Analysis Report [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Table of Contents
1. Osteosarcoma Market Report Introduction
2. Executive Summary for Osteosarcoma
3. SWOT analysis of Osteosarcoma
4. Osteosarcoma Patient Share (%) Overview at a Glance
5. Osteosarcoma Market Overview at a Glance
6. Osteosarcoma Disease Background and Overview
7. Osteosarcoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Osteosarcoma
9. Osteosarcoma Current Treatment and Medical Practices 1
0. Osteosarcoma Unmet Needs
11. Osteosarcoma Emerging Therapies
12. Osteosarcoma Market Outlook
13. Country-Wise Osteosarcoma Market Analysis (2019-2032)
14. Osteosarcoma Market Access and Reimbursement of Therapies
15. Osteosarcoma Market Drivers
16. Osteosarcoma Market Barriers
17. Osteosarcoma Appendix
18. Osteosarcoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteosarcoma-market-set-for-groundbreaking-expansion-by-2032-forecasts-delveinsight-aurora-biopharma-bioatla-iovance-biotherapeutics-isofol-medical-ab-bristolmyers-squibb-cellestia-biotech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech here
News-ID: 3954742 • Views: …
More Releases from ABNewswire
QuoteIQ Disrupts Pest Control Industry with AI-Powered Management Platform as Co …
Revolutionary All-in-One Solution Delivers Superior Route Optimization, Customer Communication, and Automation Features Missing from Outdated Competitors
QuoteIQ, the fastest-growing field service management platform, is disrupting the pest control industry as companies increasingly abandon outdated legacy systems like GorillaDesk in favor of QuoteIQ's comprehensive AI-powered platform. The migration reflects a growing demand for modern automation, advanced customer communication tools, and sophisticated route optimization capabilities that traditional pest control software simply cannot deliver.
Bottom…
Family-Owned Chloe Athena Enters E-commerce Market with Inclusive Fashion for Wo …
New Retail Platform Challenges Corporate Giants with Personal Service and Multi-Generational Style Options
Chloe Athena (https://chloeathena.com), a newly established family-owned retail company, has entered the e-commerce market with a mission to provide trendy, modern fashion for women of all ages. The startup offers an alternative to corporate fashion retailers by combining personal service with styles that appeal to teenagers, working professionals, and mature women alike.
Despite challenging economic conditions, the company's founders…
Author Romona Norton Releases New Children's Book - Milo's Pet Problem
Children's author Romona Norton is back with a brand-new laugh-out-loud story that will have kids giggling from start to finish. Milo's Pet Problem is the delightful tale of a boy with a big imagination and an even bigger determination: finding the perfect pet.
One Boy. Too Many Wild Ideas. The Hilarious Search for the Perfect Pet Begins!
Milo has trees to climb, rivers to splash in, and endless adventures at his fingertips-but…
Bitezar's Food Rescue Marketplace Brings Sustainable Shopping Revolution to Nort …
A groundbreaking new marketplace is transforming how North Austin residents shop for groceries while simultaneously addressing the critical issue of food waste.
AUSTIN, TX - Bitezar, Inc., an Austin-based technology startup, has launched its innovative platform that connects local grocery stores and restaurants with cost-conscious consumers, offering surplus and near-expiration food items at substantial discounts through a user-friendly mobile app and web interface.
The platform's launch comes at a pivotal time when…
More Releases for Osteosarcoma
Osteosarcoma Drug Market Hits New High | Major Giants AstraZeneca,Pfizer,Amgen,
HTF MI just released the Global Osteosarcoma Drug Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major companies profiled in Osteosarcoma Drug Market are: Pfizer, Amgen, Bayer,…
Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuti …
The Osteosarcoma market growth is driven by factors like increase in the prevalence of Osteosarcoma, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Osteosarcoma market report [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Osteosarcoma market size, share, Osteosarcoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Osteosarcoma market…
Exploring the Osteosarcoma Drug Market: Trends, Opportunities, and Challenges
Osteosarcoma, a rare and aggressive bone cancer primarily affecting adolescents and young adults, has garnered significant attention in the pharmaceutical sector due to its complex treatment requirements and evolving drug landscape. This guest post delves into the osteosarcoma drug market, providing insights into its current state, opportunities, challenges, and future trends.
Introduction
Osteosarcoma is the most common primary malignant bone tumor, often occurring in the long bones of the arms and legs.…
Osteosarcoma Market Size, Share, Trends & Forecast - 2034
Overview:
According to the IMARC Group, the osteosarcoma market exhibited a market size of US$ 880.9 Million in the year 2023 and is projected at a CAGR of 4.68% during 2024-2034. This can be attributed to the growing use of combination therapy involving neoadjuvant chemotherapy and surgical resection, which improves treatment outcomes in patients and reduces the risk of cancer relapse.
The osteosarcoma market report offers a comprehensive analysis of the market…
Osteosarcoma Market Report 2023-2033 | Industry Size, Growth and Latest Insights
Market Overview:
The osteosarcoma market is expected to exhibit a CAGR of 4.87% during 2023-2033. The report offers a comprehensive analysis of the osteosarcoma market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally,…
Pediatric Osteosarcoma Therapeutics Market Insights, Forecast to 2031
The report extensively examines the global Pediatric Osteosarcoma Therapeutics market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Pediatric Osteosarcoma Therapeutics. For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global…
